The 2018 OPPS final rule, effective January 1, 2018, will drastically reduce payments for drugs purchased under the 340B drug discount program.  This policy will have a significant financial impact on hospitals and will add potential regulatory burden as well. This presentation will delve into what's needed to get paid for a drug, where the information comes from and who will be responsible for ensuring accuracy and completeness of data being submitted.  A cross functional multidisciplinary approach to revenue cycle management is essential with expensive specialty drugs commanding a larger percentage of the drug spend and payors competing with clinicians for control of that spend. 2018 OPPS 340B payments and newly proposed legislation also will be discussed.

 

1. Describe the recent modifications to the 340B drug discount program.

2. Outline the challenges that 340B presents for hospital pharmacy executives.

3. Detail methods of driving savings as a result of the 340B program.